CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter TrialNirali N. Shah, Richard Aplenc, Susanne H.C. Baumeister et al.|Blood|2023Cited by 62
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AMLSwati Naik, Saar Gill, Richard Aplenc et al.|Blood Advances|2025Cited by 7